02162.HK
Keymed Biosciences Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 79.75
−0.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 697.8M | 428.1M | 354.1M | 100.1M |
| Cost of Revenue | 303.1M | 181.3M | 12.2M | 36.9M | 2.6M |
| Gross Profit | 1.4B | 516.5M | 415.9M | 317.2M | 97.5M |
| Operating Expenses | |||||
| R&D Expense | 1.5B | 704.8M | 735.2M | 596.3M | 507.4M |
| SG&A Expense | 895.5M | 395.4M | 298.8M | 177.0M | 133.9M |
| General & Admin Expense | 187.2M | — | 187.9M | 177.0M | 133.9M |
| Selling & Marketing Expense | 225.2M | — | 110.9M | — | — |
| Other Expenses | 1.2M | 1.2M | — | (21.3M) | — |
| Total Operating Expenses | 2.4B | 1.1B | 1.0B | 752.0M | 641.3M |
| Cost and Expenses | 2.7B | 1.3B | 1.0B | 788.9M | 643.9M |
| Operating Income (EBIT) | (960.8M) | (584.9M) | (618.1M) | (434.8M) | (543.8M) |
| Non-Operating | |||||
| Interest Income | 122.0M | 68.4M | 88.3M | 88.3M | 54.3M |
| Interest Expense | 15.6M | 16.5M | 18.5M | 17.3M | 8.2M |
| Net Interest Income | 106.4M | 51.9M | 69.9M | 71.1M | 45.9M |
| Other Non-Op Income/Expense | 1.8B | 77.6M | 109.5M | 78.6M | 240.2M |
| Non-Operating Income (excl Interest) | 20.0M | — | 8.0M | (95.9M) | (182.9M) |
| EBT (Pre-Tax Income) | 795.5M | (507.2M) | (508.6M) | (356.2M) | (303.6M) |
| Income Tax Expense | 288.2M | 1.8M | 6.3M | 1.6M | — |
| Bottom Line | |||||
| Net Income | 506.9M | (509.1M) | (515.2M) | (359.4M) | (308.1M) |
| Earnings from Cont. Ops | 507.3M | (509.1M) | (514.9M) | (357.8M) | (303.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 506.9M | (509.1M) | (515.2M) | (359.4M) | (308.1M) |
| Per Share | |||||
| Basic EPS | HK$1.80 | (HK$1.86) | (HK$1.97) | (HK$1.37) | (HK$1.18) |
| Diluted EPS | HK$1.76 | (HK$1.86) | (HK$1.97) | (HK$1.37) | (HK$1.18) |
| Revenue Per Share | HK$5.98 | HK$2.55 | HK$1.63 | HK$1.35 | HK$0.38 |
| Shares | |||||
| Basic Shares Outstanding | 283.5M | 274.0M | 261.9M | 261.4M | 261.1M |
| Diluted Shares Outstanding | 286.3M | 274.0M | 261.9M | 261.4M | 261.1M |
| Profitability Metrics | |||||
| EBITDA | (836.0M) | (489.4M) | (574.5M) | (269.8M) | (259.3M) |
| D&A | 144.8M | 95.5M | 51.6M | 69.2M | 36.1M |
| EBIT | (980.8M) | (584.9M) | (626.1M) | (338.9M) | (295.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026